Personalized treatment strategies based on genetics at diagnosis

Join the Study

Question

Can we treat newly diagnosed myeloma patients with personalized care based on their genetics at diagnosis? 

Description

The University of Miami team is creating a computational Individualized Risk model for Myeloma (IRMMa) to help newly diagnosed patients understand their best treatment path based on their genetics at diagnosis. They do this by performing genetic testing on bone marrow biopsy slides performed at diagnoses. They then review how patients were treated to identify which myeloma therapies and combinations are most effective. They have completed this testing on many University of Miami patients and need more patients to participate to build a model that is statistically accurate. Multiple myeloma is a single disease and when patients are broken into subcategories, data from thousands of patients are needed to accurately predict outcomes. 

Impact

Myeloma patients should be treated personally and not simply given the same combination therapies for the same amount of time. Your support in joining this study could identify optimal, personalized treatment for each and every myeloma patient.  The study could eliminate overtreatment or undertreatment of patients and help identify curative paths forward for newly diagnosed patients. This study could take 10 years if restricted to patients only at the University of Miami. This is a critically important study and we invite your participation. 

Type

Bone marrow slides and data connections

Time 

3-5 minutes

Research Partners

Ola Landgren, MD, PhD, University of Miami and Benjamin Diamond, MD, University of Miami

Who Can Join

Multiple myeloma patients willing to share 5 unstained slides from their original bone marrow biopsy and willing to connect their medical records

Join the Study